Effect of Shunthi Tablet in Amajirna

• Register: CTRI
• Last refreshed on: 24 November 2021
• Main ID: CTRI/2016/01/006575
• Date of registration: 28-01-2016
• Prospective Registration: Yes
• Primary sponsor: IPGT RA GAU Jamnagar India
• Public title: Effect of Shunthi Tablet in Amajirna
• Scientific title: Critical study of Rogotpatti Sidhdhanta and its application in management of Amajirna
• Date of first enrolment: 02-02-2016
• Target sample size: 30
• Recruitment status: Not Yet Recruiting
• URL: http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13964
• Study type: Interventional
• Study design: Single Arm Trial; Method of generating randomization sequence:Not Applicable Method of allocation concealment:Not Applicable Blinding and masking:Not Applicable
• Phase: Phase 1/ Phase 2

Countries of recruitment

India

Contacts

• Name: Prof M K Vyas
• Affiliation: IPGT RA Jamnagar Gujarat

• Name: Dr A S Baghel
• Affiliation: IPGT RA Jamnagar Gujarat

Key inclusion & exclusion criteria

Inclusion criteria: Patients having signs and symptoms of Amajirna mentioned in classics Patients having age between 20 -50 years Patients will be selected without any bar of race religion and sex


Exclusion criteria: Patients suffering from chronic major illness like Jaundice AIDS Cancer Tuberculosis Diabetes Mellitus etc

Patient having symptoms of Vidagdhajirna Vishtabdhajirna Rasasheshajirna and Dinapaki Ajirna

Patient having age less than 20 years and more than 50 years



Age minimum:
Age maximum:
Gender:

Health Condition(s) or Problem(s) studied

Health Condition 1: null- Indigestion

Intervention(s)

Intervention1: Shunthi Tablet: 2 tab 500 mg each thrice per day after meal duration 10 days
Control Intervention1: Shunthi Tablet: 2 tab 500 mg each thrice per day after meal duration 10 days

Primary Outcome(s)

Improvement will be assessed on the basis of

relief found in cardinal symptoms of

disease

Progress in the signs and symptoms

based on the standard pattern will be applied

before and after treatmentTimepoint: 10 days

Secondary Outcome(s)

Improvement will be assessed on the basis of

relief found in cardinal symptoms of

disease

Progress in the signs and symptoms

based on the standard pattern will be applied

before and after treatmentTimepoint: less than 10 days

Secondary ID(s)

NIL

Source(s) of Monetary Support

IPGT RA GAU Jamnagar Gujarat India

Ethics review

Status: Approved
Approval date: 25/08/2015
Contact:

INSITUTIONAL ETHICS COMMITTEE